BG Medicine, Inc. (BGMD) Reports In-Line Q1 Loss of 8c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
BG Medicine Reports First Quarter 2014 Financial Results
May 14, 2014 7:30 AM EDTNet Loss Reduced by 60% and Operating Cash Burn Cut by 44% From First Quarter 2013
Continued Progress Made Toward Delivering on Critical Catalysts for Growth
WALTHAM, Mass., May 14, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq: BGMD), the developer of the BGM Galectin-3® Test, today reported financial results for the first quarter ended March 31, 2014.
The Company reported... More
